Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study.

Amitava Banerjee, Deirdre Lane, C Torp-Pedersen, Gregory Lip

Research output: Contribution to journalArticle

270 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study.'. Together they form a unique fingerprint.

Medicine & Life Sciences